This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 2000;284:2711.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The FDA has approved labeling for a new use for the antihypertensive drug ramipril (Altace, Aventis Pharmaceuticals, Kansas City, Mo), an ACE inhibitor, to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes.

The new indication is limited to patients 55 years or older who are at high risk for developing a major cardiovascular event because of history of coronary artery disease, stroke, peripheral vascular disease, or type 1 or 2 diabetes that is accompanied by at least one other cardiovascular risk factor, such as hypertension, cigarette smoking, elevated total cholesterol levels, low HDL level, or proteinuria. Ramipril can be used in addition to other treatment.

The new use was approved on the basis of the Heart Outcomes Prevention Evaluation study (HOPE), a multicenter, randomized trial of 9541 patients (4645 of whom were taking ramipril). Participants had the conditions described above and were normotensive or being treated . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?